ArticleBMJ evidence-based medicine2024
Rapid access to innovative medicinal products while ensuring relevant health technology assessment. Position of the French National Authority for Health.
Abstract read
In one paragraph
Article in BMJ evidence-based medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 3 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Covariate selection and adjustment for efficacy and safety endpoints in indirect comparative effectiveness analyses of CAR-T-cell therapies for large B-cell lymphoma: a systematic review.Journal of comparative effectiveness research · 2026Pooled it
- Acceptance of external control arms by HTA agencies: a review of oncology submissions in France, England, Germany and Norway from 2021 to 2023.British journal of cancer · 2025Pooled it
- Advancing the role of real-world evidence in comparative effectiveness research.Journal of comparative effectiveness research · 2024Pooled it
- Article
- Mapping the Use of Real-World Evidence Across the EU Health Technology Assessment Regulation: Methodological Considerations, Challenges, and Opportunities for Harmonization.Journal of market access & health policy · 2026Article
- Article
- Acceptability of external control-arm use in nononcology health technology assessment submissions.Journal of comparative effectiveness research · 2026Article
- Enhancing confidence in complex health technology assessments by using real-world evidence: highlighting existing strategies for effective drug evaluation.BMC medical research methodology · 2025Review
- Identification of treatment effect modifiers and prognostic factors in newly diagnosed and relapsed or refractory multiple myeloma.Journal of comparative effectiveness research · 2025Article
- An External Control Arm for the Oral Factor XIa Inhibitor Asundexian Phase 2 Trial in Atrial Fibrillation (PACIFIC-AF) Using Electronic Health Records.Cardiology and therapy · 2025Article
- Mapping methods gaps between EU joint clinical assessments and local health technology assessment decision-making: an environmental scan of guidance in select EU markets and harmonization challenges.Journal of comparative effectiveness research · 2025Review
- Sustainability and Time Trends in Electronic Patient-Reported Outcome Assessment in Routine Cancer Care: Systematic Scoping Review and Follow-Up Survey.Journal of medical Internet research · 2025Article
- Review
- The PERMIT guidelines for designing and implementing all stages of personalised medicine research.Scientific reports · 2024Article
- New cancer medicines in Europe 2010-2020: comparison of medicines with or without extensions of indications.BMJ open · 2024Article
- Why is target trial emulation not being used in health technology assessment real-world data submissions?Journal of comparative effectiveness research · 2024Article
- EU HTA Joint Clinical Assessment: are patients with rare disease going to lose out?Journal of comparative effectiveness research · 2024Article
- Can requests for real-world evidence by the French HTA body be planned? An exhaustive retrospective case-control study of medicinal products appraisals from 2016 to 2021.International journal of technology assessment in health care · 2024Article
- Navigating the unknown: how to best 'reflect' standard of care in indications without a dedicated treatment pathway in health technology assessment submissions.Journal of comparative effectiveness research · 2024Review
- R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 14.Journal of comparative effectiveness research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Antoine VanierHealth Technology Assessment Department, Haute Autorité de Santé, La Plaine Saint-Denis, France a.vanier@has-sante.fr.
Judith FernandezHealth Technology Assessment Department, Haute Autorité de Santé, La Plaine Saint-Denis, France.ORCID 0000-0003-3923-7139
Sophie KelleyHealth Technology Assessment Department, Haute Autorité de Santé, La Plaine Saint-Denis, France.
Lise AlterHealth Technology Assessment Department, Haute Autorité de Santé, La Plaine Saint-Denis, France.
Patrick SemenzatoHealth Technology Assessment Department, Haute Autorité de Santé, La Plaine Saint-Denis, France.
Corinne AlbertiECEVE, Inserm - Université Paris Cité, Paris, France.
Sylvie ChevretUMR U1153 - ECSTRRA Team, Inserm - Université Paris Cité, Paris, France.
Dominique CostagliolaInstitut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), Inserm - Sorbonne Universite, Paris, France.
Michel CucheratPharmacology Department, Université Claude Bernard Lyon 1, Villeurbanne, France.
Bruno FalissardUMR U1018 CESP, Inserm - UVSQ - AP-HP - Université Paris-Saclay, Paris, France.
François GueyffierPôle de Santé Publique - Unité des Bases de Données Cliniques et Epidemiologiques, Hospices Civils de Lyon, Lyon, France.
Jérôme LambertUMR U1153 - ECSTRRA Team, Inserm - Université Paris Cité, Paris, France.
Etienne LenglinéHematology Department, AP-HP Hopital Saint-Louis, Paris, France.
Clara LocherCIC 1414 - Service de Pharmacologie Clinique - Irset UMR S1085, Inserm - CHU de Rennes - EHESP - Rennes 1 University, Rennes, France.ORCID 0000-0002-8212-4351
Florian NaudetCIC 1414 - Irset UMR S1085, Inserm - CHU de Rennes - EHESP - Rennes 1 University, Rennes, France.ORCID 0000-0003-3760-3801
Raphael PorcherCentre de Recherche Epidémiologie et Statistiques (CRESS-UMR1153), Inserm - Université Paris Cité, Paris, France.
Rodolphe ThiébautBordeaux Population Health - SISTM - Service d'Information Médicale, Inserm - Inria - Bordeaux 1 University - CHU de Bordeaux, Bordeaux, France.
Muriel VrayUnité d'Epidémiologie des Maladies Emergentes, Institut Pasteur - Inserm, Paris, France.
Sarah ZoharCentre de Recherche des Cordeliers, Inserm - Université Paris-Cité - Sorbonne Université, Paris, France.
Pierre CochatScientific Board, Haute Autorité de Santé, La Plaine Saint-Denis, France.
Dominique Le GuludecScientific Board, Haute Autorité de Santé, La Plaine Saint-Denis, France.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Drug IndustryTechnology Assessment, BiomedicalHumansDrug DevelopmentHealth Care Economics and OrganizationsHealth Care Quality, Access, and Evaluation
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.